Targeted Pulse Quiz: September 1

The combination of benmelstobart with anlotinib led to efficacy improvements in patients with advanced renal cell carcinoma vs sunitinib.

In this episode of Targeted Talks, James M. Foran, MD, discusses the presentation and diagnosis of blastic plasmacytoid dendritic cell neoplasm.

The phase 3 HypoG-01 trial found moderately hypofractionated radiation therapy had similar lymphedema risk to standard therapy in patients with early breast cancer.

In this episode of Emerging Experts, Paolo Tarantino, MD, discusses the latest developments in breast cancer research and treatment.

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed the data behind loncastuximab and whether participants with use this treatment for patients with diffuse large B-cell lymphoma in the first article of a 2-part series.

Inavolisib showed promise in treating patients with PIK3CA-mutated solid tumors, demonstrating favorable safety and disease control.